Following and complementing previous studies, here we exploited biased and unbiased MD simulations to comprehensively characterize the binding/dissociation mechanism of H3B, an SM currently in clinical trials, which preferentially triggers lethality in cancer cells and patient-derived xenograft models bearing mutations of the splicing factors SF3B1 and SRSF2 [23]. Here, SRSF2 is linked to cancer.